Literature DB >> 16496307

Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.

Manuel Hernández-Guerra1, Juan C García-Pagán, Juan Turnes, Pablo Bellot, Ramón Deulofeu, Juan G Abraldes, Jaime Bosch.   

Abstract

Patients with cirrhosis show intrahepatic endothelial dysfunction, characterized by an impaired flow-dependent vasorelaxation. This alteration is responsible for the marked postprandial increase in portal pressure and is attributed to an insufficient release of nitric oxide (NO). Ascorbic acid reverts endothelial dysfunction in other vascular disorders, via the increase of NO bioavailability through the neutralization of superoxide anions, thus preventing the scavenging of NO by superoxide. This study examined whether acute ascorbic acid administration might improve endothelial dysfunction in cirrhosis. Thirty-seven portal hypertensive patients with cirrhosis had measurements of hepatic and systemic hemodynamics, ascorbic acid, and malondialdehyde (MDA). Patients were randomly allocated to receive ascorbic acid (3 g, intravenously, n = 15) or placebo (n = 12) followed by a liquid meal. A third group received ascorbic acid followed by a sham meal (n = 10). Measurements were repeated after 30 minutes (hepatic venous pressure gradient at 15 and 30 minutes). Patients with cirrhosis had significantly lower ascorbic acid levels and higher MDA than healthy controls. Ascorbic acid significantly reduced MDA levels and markedly attenuated the postprandial increase in the hepatic venous pressure gradient (4% +/- 7% vs. 18% +/- 10% in placebo at 30 minutes, P < .001). Ascorbic acid followed by sham meal did not modify hepatic or systemic hemodynamics. In conclusion, patients with cirrhosis exhibited intrahepatic endothelial dysfunction, associated with decreased levels of ascorbic acid and increased levels of MDA. Ascorbic acid improved intrahepatic endothelial dysfunction, blunting the postprandial increase in portal pressure. These results encourage the performance of further studies testing antioxidants as adjunctive therapy in the treatment of portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496307     DOI: 10.1002/hep.21080

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

Review 1.  Nutritional support for liver disease.

Authors:  Ronald L Koretz; Alison Avenell; Timothy O Lipman
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 5.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

Review 6.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

Review 7.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 8.  Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Liver Int       Date:  2011-07-05       Impact factor: 5.828

Review 9.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

10.  Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.

Authors:  Enric Reverter; Francisco Mesonero; Susana Seijo; Javier Martínez; Juan G Abraldes; Beatriz Peñas; Annalisa Berzigotti; Ramon Deulofeu; Jaume Bosch; Agustín Albillos; Joan Carles García-Pagán
Journal:  Am J Gastroenterol       Date:  2015-06-16       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.